CA-LIVEACTION
10.8.2021 15:02:04 CEST | Business Wire | Press release
SITA, the leading IT provider to the air transport industry, and LiveAction , the leader in network performance management, today announced the availability of a new reporting solution that gives customers complete visibility and service assurance across WAN and SD-WAN deployments. Based on LiveAction’s LiveSP , the SITA SDN Reporting Platform is available as part of SITA Service Management Assurance, an industry-leading Service Management offering that helps customers achieve maximum value from SITA subscribed services.
LiveAction provides end-to-end visibility into network and application performance from a centralized, single pane of glass dashboard. The platform unifies networking data by collecting, analyzing and reporting on diverse network telemetry datasets, allowing organizations to optimize network, application and end-user performance. This helps network operations teams improve visibility across the entire hybrid network and track network usage, application performance, SD-WAN performance, COS information, cloud traffic usage, network latency and much more. Designed for service providers, LiveSP enables SITA to provide enhanced customer visibility and business insights for SITA Connect services – offering secure, reliable, and flexible network connectivity solutions that deliver ever-improving passenger experiences globally.
“Partnering with LiveAction has helped us develop a world-class service management offering for software-defined networking (SDN), including the co-development of unique reporting features that bring real value to our customers,” said Martin Smillie, Vice-President of Communications and Data Exchange at SITA. “The out-of-the-box integration with existing SDN vendors has reduced time to market with a robust and comprehensive solution.”
With many large airline customers already onboarded in the platform, SITA will be further enhancing the offering by integrating LiveAction LiveWire, a network packet capture solution. This will enable customers to extend network visibility and application troubleshooting and conduct deep forensic analysis if needed.
“Today’s networks are complex and changing rapidly. Having complete visibility into network and application performance is critical to delivering high-performance network services and being able to troubleshoot issues that arise,” said Stephen Stuut, Chief Executive Officer at LiveAction. “We’re excited to be working with SITA to help ensure their customers have world class connectivity and performance across global networks. This has been a complete team effort on both sides.”
For more information on SITA Service Management Assurance and the new reporting solution with LiveSP go to SITA | SITA Service Management .
About SITA
SITA is the air transport industry's IT provider, delivering solutions for airlines, airports, aircraft and governments. Our technology powers more seamless, safe and sustainable air travel. For further information, go to www.sita.aero .
About LiveAction
LiveAction provides end-to-end visibility into network and application performance from a single pane of glass. This gives enterprises confidence that the network is meeting business objectives, offers IT administrators full visibility for better decision making, and reduces the overall cost of operations. By unifying and simplifying the collection, correlation and presentation of network and application data, LiveAction empowers network professionals to proactively and quickly identify, troubleshoot and resolve issues across complex networks. Learn more at https://www.liveaction.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210810005037/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom